ALZNHealthcare · BiotechnologyALZN Stock Forecast: Alzamend Neuro, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Alzamend Neuro, Inc. hold a median 12-month price target of $25 — +1765.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ALZN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Alzamend Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Momentum (7): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Alzamend Neuro, Inc. — and when they’d sell — is the membership.
ALZN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ALZN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1765.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | $42 → $28 |
| 25 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Aug 2025 | Ascendiant Capital | Maintains | Buy | — |
| 17 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 16 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 11 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Apr 2023 | Maxim Group | Initiates | Buy | $1.50 |
| 1 Oct 2021 | Ascendiant Capital | Initiates | Buy | $8.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ALZN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Alzamend Neuro, Inc. (ALZN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.5×
- Price / sales
- —
- Price / book
- 2.3×
- EV / EBITDA
- −0.6×
Cheaper than 79% of US stocks
Cheaper than 41% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −373.2%
- Return on assets
- −164.0%
- Dividend yield
- —
Higher than 3% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ALZN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALZN appears on the weeks it earns a place.
Frequently asked questions about ALZN stock
What is the ALZN stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Alzamend Neuro, Inc. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ALZN stock a buy right now?
Of the 1 analysts covering Alzamend Neuro, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alzamend Neuro, Inc. 16 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ALZN?
As at 1 Aug 2026, Alzamend Neuro, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
Will ALZN stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1765.7% from the last close, and Ticker Nerd's factor model ranks Alzamend Neuro, Inc. 16 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ALZN stock forecast for 2030?
No analyst covering Alzamend Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALZN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
How has ALZN stock performed over the past year?
Alzamend Neuro, Inc. returned -39.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Alzamend Neuro, Inc. do?
Alzamend Neuro Inc. is a clinical-stage biopharmaceutical company headquartered in Atlanta, Georgia, focused on developing novel treatments for neurodegenerative and psychiatric disorders.
About Alzamend Neuro, Inc.
Alzamend Neuro Inc. is a clinical-stage biopharmaceutical company headquartered in Atlanta, Georgia, focused on developing novel treatments for neurodegenerative and psychiatric disorders. The company's primary pipeline consists of two therapeutic drug candidates: AL001, a patented ionic cocrystal technology that delivers lithium combined with proline and salicylate for treating Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder; and ALZN002, a cell-based therapeutic vaccine designed to restore the immune system's ability to combat Alzheimer's disease. Both product candidates are licensed from the University of South Florida Research Foundation under exclusive worldwide licenses. AL001 is currently in clinical development, with recent Phase II trials demonstrating bioequivalence to standard lithium carbonate while showing numerically superior lithium delivery to the brain. The company collaborates with Massachusetts General Hospital as its contract research organization to advance clinical trials across multiple therapeutic indications affecting over 600 million people globally.
CEO Mr. Stephan Jackman · 4 employees · United States · https://www.alzamend.com